Hongliang Shi

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Richard I. Fisher, Steven H. Bernstein, Brad S. Kahl et al. · Journal of Clinical Oncology · 2006 · 708 citations

Medicine, Hematology, Oncology +15

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Shaji Kumar, Ian W. Flinn, Paul G. Richardson et al. · Blood · 2012 · 451 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

André Goy, Steven H. Bernstein, Brad S. Kahl et al. · Annals of Oncology · 2008 · 340 citations · Full text

Medicine, Hematology, Oncology +13

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Richard D. Kim, Debashis Sarker, Tim Meyer et al. · Cancer Discovery · 2019 · 250 citations · Full text

Medicine, Oncology, Pharmacology +17

Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team

Brenda Crowe, H. Amy Xia, Jesse A. Berlin et al. · Clinical Trials · 2009 · 120 citations

Pharmacy, Pharmaceutical Policy, Drug Approval Processes +16